The risk of tuberculosis in patients treated with TNF antagonists

References

• Bradley JR. TNF-mediated inflammatory disease. J. Pathol.214(2), 149–160 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum.48(8), 2122–2127 (2003).
   PubMed Web of Science ®Google Scholar
• Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol.161(1), 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum.52(6), 1766–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur. Respir. J. DOI: 10.1183/09031936.00028510 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet2(8657), 244–247 (1989).
   PubMed Web of Science ®Google Scholar
• Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw.6(4), 225–230 (1995).
   PubMed Web of Science ®Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA89(20), 9784–9788 (1992).
   PubMed Web of Science ®Google Scholar
• Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology77(4), 510–514 (1992).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity10(3), 387–398 (1999).
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis.69(6), 976–986 (2010).
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost–effectiveness. Health Technol. Assess.10(42), III–IV, XI–XIII, 1–229 (2006).
   PubMed Web of Science ®Google Scholar
• Keystone E, Genovese MC, Klareskog L et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann. Rheum. Dis.69(6), 1129–1135 (2010).
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum.38(4), 499–505 (1995).
   PubMed Web of Science ®Google Scholar
• Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-α, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur. J. Med. Res.5(12), 507–511 (2000).
   PubMedGoogle Scholar
• Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut34(12), 1705–1709 (1993).
   PubMed Web of Science ®Google Scholar
• Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol.96(1), 146–151 (1994).
   PubMed Web of Science ®Google Scholar
• Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin. Exp. Rheumatol.24(5), 587–593 (2006).
   PubMedGoogle Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology115(1), 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect. Immun.64(3), 683–690 (1996).
   PubMed Web of Science ®Google Scholar
• Fenton MJ. Macrophages and tuberculosis. Curr. Opin. Hematol.5(1), 72–78 (1998).
   PubMedGoogle Scholar
• Fischl MA, Daikos GL, Uttamchandani RB et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann. Intern. Med.117(3), 184–190 (1992).
   PubMed Web of Science ®Google Scholar
• Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-mediated uptake and tumor necrosis factor-α-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J. Immunol.152(2), 743–753 (1994).
   PubMed Web of Science ®Google Scholar
• Kurashima K, Mukaida N, Fujimura M et al. Elevated chemokine levels in bronchoalveolar lavage fluid of tuberculosis patients. Am. J. Respir. Crit. Care Med.155(4), 1474–1477 (1997).
   PubMedGoogle Scholar
• Jones BW, Heldwein KA, Means TK, Saukkonen JJ, Fenton MJ. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann. Rheum. Dis.60(Suppl. 3), iii6–iii12 (2001).
   PubMed Web of Science ®Google Scholar
• Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell136(1), 37–49 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor JL, Hattle JM, Dreitz SA et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect. Immun.74(11), 6135–6144 (2006).
   PubMed Web of Science ®Google Scholar
• Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science327(5964), 466–469 (2010).
   PubMed Web of Science ®Google Scholar
• Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-α controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J. Immunol.166(11), 6728–6734 (2001).
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol.168(9), 4620–4627 (2002).
   PubMed Web of Science ®Google Scholar
• Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. Tumor necrosis factor α regulates in vivo intrapulmonary expression of ICAM-1. Am. J. Pathol.142(6), 1739–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. β-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect. Immun.70(4), 1684–1693 (2002).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS18(2), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med.25(6), 556–566 (1999).
   PubMed Web of Science ®Google Scholar
• Bruns H, Meinken C, Schauenberg P et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest.119(5), 1167–1177 (2009).
   PubMed Web of Science ®Google Scholar
• Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med.192(1), 117–122 (2000).
   PubMed Web of Science ®Google Scholar
• Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun.69(3), 1847–1855 (2001).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity2(6), 561–572 (1995).
   PubMed Web of Science ®Google Scholar
• Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. J. Exp. Med.193(2), 239–246 (2001).
   PubMed Web of Science ®Google Scholar
• Ehlers S, Holscher C, Scheu S et al. The lymphotoxin β receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J. Immunol.170(10), 5210–5218 (2003).
   PubMedGoogle Scholar
• Lin PL, Myers A, Smith L et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum.62(2), 340–350 (2010).
   PubMedGoogle Scholar
• Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity29(2), 283–294 (2008).
   PubMed Web of Science ®Google Scholar
• Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect. Dis.8(10), 601–611 (2008).
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum.58(5), 1248–1257 (2008).
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis.13(11), 1323–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum.57(5), 756–761 (2007).
   PubMed Web of Science ®Google Scholar
• Seong SS, Choi CB, Woo JH et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J. Rheumatol.34(4), 706–711 (2007).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345(15), 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum.50(2), 372–379 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis.38(9), 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin. Infect. Dis.43(6), 717–722 (2006).
   PubMed Web of Science ®Google Scholar
• Mines D, Novelli L. Antirheumatic drugs and the risk of tuberculosis. Clin. Infect. Dis.44(4), 619–620; author reply 620–611 (2007).
   PubMedGoogle Scholar
• Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum.60(7), 1884–1894 (2009).
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Canhao H, Silva C et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor α antagonists: the Portuguese experience. Acta Reumatol. Port.31(3), 247–253 (2006).
   PubMedGoogle Scholar
• Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis.69(3), 522–528(2010).
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest124(1), 177–185 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J.33(5), 956–973 (2009).
   PubMed Web of Science ®Google Scholar
• Dinser R, Fousse M, Sester U et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-α blocking drugs using a novel flow-cytometric interferon-γ release assay. Rheumatology (Oxford)47(2), 212–218 (2008).
   PubMedGoogle Scholar
• Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med.149(3), 177–184 (2008).
   PubMed Web of Science ®Google Scholar
• Diel R, Goletti D, Ferrara G et al. Interferon-{γ} release assays for the diagnosis of latent M. tuberculosis infection: a systematic review and meta-analysis. Eur. Respir. J. DOI: 10.1183/09031936.00115110 (2010) (Epub ahead of print).
   Google Scholar
• Aichelburg MC, Rieger A, Breitenecker F et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin. Infect. Dis.48(7), 954–962 (2009).
   PubMed Web of Science ®Google Scholar
• Clark SA, Martin SL, Pozniak A et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin. Exp. Immunol.150(2), 238–244 (2007).
   PubMed Web of Science ®Google Scholar
• Mori T. Usefulness of interferon-γ release assays for diagnosing TB infection and problems with these assays. J. Infect. Chemother.15(3), 143–155 (2009).
   PubMedGoogle Scholar
• Cobanoglu N, Ozcelik U, Kalyoncu U et al. Interferon-γ assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-α blockers. Int. J. Tuberc. Lung Dis.11(11), 1177–1182 (2007).
   PubMedGoogle Scholar
• Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann. Rheum. Dis.67(1), 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunosorbent assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum. J. Rheumatol.35(7), 1464 (2008).
   PubMedGoogle Scholar
• Bocchino M, Matarese A, Bellofiore B et al. Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment. Eur. J. Clin. Microbiol. Infect. Dis.27(10), 907–913 (2008).
   PubMed Web of Science ®Google Scholar
• Bartalesi F, Vicidomini S, Goletti D et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur. Respir. J.33(3), 586–593 (2009).
   PubMed Web of Science ®Google Scholar
• Murakami S, Takeno M, Kirino Y et al. Screening of tuberculosis by interferon-γ assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb.)89(2), 136–141 (2009).
   PubMed Web of Science ®Google Scholar
• Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J. Rheumatol.36(3), 546–551 (2009).
   PubMed Web of Science ®Google Scholar
• Laffitte E, Janssens JP, Roux-Lombard P et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-γ release assay vs. tuberculin skin test. Br. J. Dermatol.161(4), 797–800 (2009).
   PubMed Web of Science ®Google Scholar
• Soborg B, Ruhwald M, Hetland ML et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J. Rheumatol.36(9), 1876–1884 (2009).
   PubMed Web of Science ®Google Scholar
• Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB Gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol.36(12), 2675–2681 (2009).
   PubMedGoogle Scholar
• Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf.5(2), 231–249 (2006).
   PubMed Web of Science ®Google Scholar
• Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Am. J. Respir. Crit. Care Med.175(8), 858; author reply 858–859 (2007).
   PubMed Web of Science ®Google Scholar
• Haroon M, Martin U, Devlin J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol. Int. DOI: 10.1007/s00296-010-1571-1576 (2010) (Epub ahead of print).
   Google Scholar
• Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann. Rheum. Dis.64(9), 1360–1361 (2005).
   PubMed Web of Science ®Google Scholar
• Sester U, Junker H, Hodapp T et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol. Dial. Transplant.21(11), 3258–3268 (2006).
   PubMedGoogle Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a joint statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am. J. Respir. Crit. Care Med.161(4 Pt 2), S221–S247 (2000).
   PubMed Web of Science ®Google Scholar
• Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax55(11), 887–901 (2000).
   PubMed Web of Science ®Google Scholar
• Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K. Recommendations for tuberculosis screening before initiation of TNF-α-inhibitor treatment in rheumatic diseases. Pneumologie63(6), 329–334 (2009).
   PubMedGoogle Scholar
• Kavanagh PM, Gilmartin JJ, O’Donnell J, O’Flanagan D. Tumour necrosis factor-α and tuberculosis: guidance from the National TB Advisory Committee. Iran. Med. J.101(1), 6–7 (2008).
   PubMedGoogle Scholar
• Beglinger C, Dudler J, Mottet C et al. Screening for tuberculosis infection before the initiation of an anti-TNF-α therapy. Swiss Med. Wkly137(43–44), 620–622 (2007).
   PubMedGoogle Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax60(10), 800–805 (2005).
   PubMed Web of Science ®Google Scholar
• Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J. Rheumatol.35(5), 776–781 (2008).
   PubMedGoogle Scholar
• Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis.62(8), 791 (2003).
   PubMed Web of Science ®Google Scholar
• Denis B, Lefort A, Flipo RM et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment. Clin. Microbiol. Infect.14(2), 183–186 (2008).
   PubMedGoogle Scholar
• Garcia Vidal C, Garau J. Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin. Infect. Dis.41(6), 915–916; author reply 916–917 (2005).
   PubMedGoogle Scholar
• Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int. J. Tuberc. Lung Dis.9(9), 1057–1058 (2005).
   PubMed Web of Science ®Google Scholar
• Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell56(5), 731–740 (1989).
   PubMed Web of Science ®Google Scholar
• Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol.171(6), 3110–3118 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol.27, 393–422 (2009).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol. Rev.226, 191–204 (2008).
   PubMed Web of Science ®Google Scholar
• Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun.65(11), 4843–4849 (1997).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology135(4), 1130–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol.7(9), 796–804 (2008).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet371(9625), 1665–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet371(9625), 1675–1684 (2008).
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med.2, 52–72 (2010).
   Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol.91, 1–44 (2006).
   PubMed Web of Science ®Google Scholar
• Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J. Immunol.178(11), 7222–7234 (2007).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol.37(3), 558–567 (2010).
   PubMed Web of Science ®Google Scholar
• Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis.68(11), 1708–1714 (2009).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med.353(11), 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med.144(12), 865–876 (2006).
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum.54(9), 2807–2816 (2006).
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum.52(7), 1986–1992 (2005).
   PubMed Web of Science ®Google Scholar
• Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J. Rheumatol.30(7), 1436–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann. Rheum. Dis.65(12), 1661–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum.61(3), 300–304 (2009).
   PubMed Web of Science ®Google Scholar
• Tam LS, Leung CC, Ying SK et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong – the role of TNF blockers in an area of high tuberculosis burden. Clin. Exp. Rheumatol.28(5), 679–685 (2010).
   PubMedGoogle Scholar
• CDC. Reported TB in the United States, 2000. US Department of Health and Human Services, CDC, Atlanta, GA, USA (2001).
   Google Scholar